Inmune Bio Inc Stock Price, News & Analysis

INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has scheduled its Q2 2025 financial results conference call and webcast for Thursday, August 7th, 2025, at 4:30 PM EDT.

The company will discuss its quarterly results for the period ending June 30, 2025, and provide a corporate update. Investors can access the call via phone using the toll-free number 1-800-225-9448 (US) or +1-203-518-9783 (international) with Conference ID: INMUNE. A live audio webcast will be available, and a transcript will be provided approximately 24 hours after the call.

INmune Bio (NASDAQ: INMB) announced plans to release a video detailing additional findings from their Phase 2 MINDFuL trial of XPro™, their selective soluble TNF inhibitor for Alzheimer's disease. The video will follow their presentation at the Alzheimer's Association International Conference (AAIC) in Toronto.

The trial demonstrated that XPro™ showed consistent benefits after 6 months in patients with amyloid-beta pathology and specific inflammatory biomarkers. Dr. Sharon Cohen will present the data at AAIC on July 29, 2025, from 2:00 to 3:30 PM ET, with the detailed video becoming available on July 31, 2025, at 4 PM ET on INmune Bio's YouTube channel.

INmune Bio (NASDAQ: INMB) will present additional analyses from its Phase 2 MINDFuL trial of XPro™, a selective soluble TNF inhibitor for Alzheimer's disease, at the AAIC in Toronto on July 29, 2025.

The trial enrolled 208 participants with early-stage Alzheimer's, randomized 2:1 to receive XPro™ or placebo. While the primary endpoint wasn't met in the overall mITT group, the treatment showed consistent benefits after 6 months in a subgroup with confirmed amyloid-beta pathology and multiple inflammation biomarkers.

Dr. Sharon Cohen will present the findings, and INmune Bio plans to publish results by mid-August while seeking strategic partnerships for XPro™'s further development.

INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has successfully closed its previously announced registered direct offering. The company sold 3,000,000 shares of common stock at $6.30 per share, raising approximately $19 million in gross proceeds before deducting fees and expenses.

The offering was priced at-the-market under Nasdaq rules and was conducted through A.G.P./Alliance Global Partners as the sole placement agent. The company plans to utilize the net proceeds for working capital purposes and general corporate procedures. The offering was executed under an effective shelf registration statement on Form S-3.

INmune Bio (NASDAQ: INMB) has reported results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF inhibitor, in early Alzheimer's Disease (AD). While the modified intent-to-treat population (n=200) did not meet the primary cognitive endpoint, a predefined subgroup of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100) showed positive results.

Key findings in the subgroup demonstrated:

• Clinical benefit on the primary endpoint EMACC (effect size: 0.27)
• Improvement on the Neuropsychiatric Inventory (effect size: -0.24)
• Biological benefit in blood levels of pTau217 (effect size: -0.20)

The treatment was well-tolerated with no occurrences of ARIA-E or ARIA-H, even in high-risk ApoE4+/+ patients. The most common adverse events were injection site reactions, affecting 80% of the XPro™ group. The company plans to file for Breakthrough Therapy Designation with the FDA and schedule an End-of-Phase 2 meeting in Q4 2025 to define the path for a pivotal trial.

INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has announced a registered direct offering of 3,000,000 shares of common stock priced at $6.30 per share. The offering, expected to close around June 30, 2025, aims to raise approximately $19 million in gross proceeds.

The offering is priced at-the-market under Nasdaq rules, with A.G.P./Alliance Global Partners serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through an effective shelf registration statement previously filed with the SEC.

INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has scheduled a conference call to present top line data from their Phase 2 MINDFuL trial in early Alzheimer's Disease. The call will take place on June 30, 2025, at 8:00 AM EDT.

Investors can access the presentation through a dial-in number (+1-800-267-6316 for US, +1-203-518-9783 for international) or via webcast. A transcript will be available within 24 hours, and a replay will be accessible through July 30, 2025.

INmune Bio announced positive results from a study showing XPro (pegipanermin) effectively reduces amyloid formation and improves brain function after traumatic brain injury (TBI) in an Alzheimer's disease model. The research, presented at Keystone Symposia's Neurodegeneration section, demonstrated that XPro administration 30 minutes post-injury inhibited solTNF/TNFR1 activity and prevented increases in key markers associated with Alzheimer's progression. The study revealed TBI triggers increased expression of TNFR1, BACE1, and Aβ42 in the hippocampus. XPro treatment successfully reduced intracellular neuronal amyloid accumulation and improved neurological outcomes in treated animals. This research is particularly significant as TBI from falls is a major concern for elderly populations at risk for Alzheimer's disease, potentially accelerating dementia onset.

INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology through innate immune system targeting, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The event will take place on May 20-21, 2025, at the InterContinental Barclay NY. The company will participate in a fireside chat and conduct one-on-one virtual meetings, with their presentation scheduled for 11:00 AM EDT.